TY - JOUR
T1 - G-CSF-stimulated BM progenitor cells supplement suboptimal peripheral blood hematopoietic progenitor cell collections for auto transplantation
AU - Seshadri, T.
AU - Al-Farsi, K.
AU - Stakiw, J.
AU - Ma, C.
AU - Saragosa, R.
AU - Franke, N.
AU - Keating, A.
AU - Crump, M.
AU - Kuruvilla, J.
N1 - Funding Information:
AK holds the Gloria and Seymour Epstein Chair in Cell Therapy and Transplantation of University Health Network and the University of Toronto. TS thanks the Haematology Society of Australia and New Zealand for financial assistance to her fellowship.
PY - 2008
Y1 - 2008
N2 - Peripheral blood hematopoietic progenitor cells (PBHC) are the standard source of support for high-dose chemotherapy because of faster recovery of marrow function. Unfortunately, a proportion of patients are unable to mobilize adequate progenitors to proceed to autologous hematopoietic cell transplant (AHCT). Granulocyte-CSF-stimulated BM-derived hematopoietic progenitor cells (BMHC) may circumvent this problem. From 1999 to 2006, 52 patients (cases) with AML, Hodgkin (HL) or non-Hodgkin's lymphoma (NHL) in whom PBHC mobilization failed underwent a G-CSF-stimulated bone marrow harvest and proceeded to AHCT. Their outcome was compared with 422 patients (controls) with AML, HL and NHL undergoing AHCT using only PBHC. Twenty-three patients received BMHC alone and 29 patients recieved a combination of PBHC and BMHC. Median engraftment time for neutrophils (>0.5 × 109/l) and platelets (>20 × 109/l) were 14 and 27 days, but significantly longer when compared with controls (11days, 11 days, P<0.0001). Patients receiving both PBHC and BMHC had faster engraftment, when compared with those receiving BMHC alone (P<0.001). In conclusion, performing an AHCT using G-CSF-stimulated BMHC in patients failing PBHC collection is feasible with faster engraftment seen in patients receiving both BMHC and PBHC over BMHC alone.
AB - Peripheral blood hematopoietic progenitor cells (PBHC) are the standard source of support for high-dose chemotherapy because of faster recovery of marrow function. Unfortunately, a proportion of patients are unable to mobilize adequate progenitors to proceed to autologous hematopoietic cell transplant (AHCT). Granulocyte-CSF-stimulated BM-derived hematopoietic progenitor cells (BMHC) may circumvent this problem. From 1999 to 2006, 52 patients (cases) with AML, Hodgkin (HL) or non-Hodgkin's lymphoma (NHL) in whom PBHC mobilization failed underwent a G-CSF-stimulated bone marrow harvest and proceeded to AHCT. Their outcome was compared with 422 patients (controls) with AML, HL and NHL undergoing AHCT using only PBHC. Twenty-three patients received BMHC alone and 29 patients recieved a combination of PBHC and BMHC. Median engraftment time for neutrophils (>0.5 × 109/l) and platelets (>20 × 109/l) were 14 and 27 days, but significantly longer when compared with controls (11days, 11 days, P<0.0001). Patients receiving both PBHC and BMHC had faster engraftment, when compared with those receiving BMHC alone (P<0.001). In conclusion, performing an AHCT using G-CSF-stimulated BMHC in patients failing PBHC collection is feasible with faster engraftment seen in patients receiving both BMHC and PBHC over BMHC alone.
UR - http://www.scopus.com/inward/record.url?scp=58149473086&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=58149473086&partnerID=8YFLogxK
U2 - 10.1038/bmt.2008.249
DO - 10.1038/bmt.2008.249
M3 - Article
C2 - 18711349
AN - SCOPUS:58149473086
VL - 42
SP - 733
EP - 737
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
SN - 0268-3369
IS - 11
ER -